AstraZeneca reports results from SERENA-2 trial

Detailed results from the SERENA-2 Phase II trial showed AstraZeneca’s next-generation oral selective estrogen receptor degrader camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, at both 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor, or ER-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy. Results will be presented in an oral presentation at the San Antonio Breast Cancer Symposium. In the overall population, camizestrant significantly reduced the risk of disease progression or death by 42% at a 75mg dose and 33% at a 150mg dose compared to Faslodex, the current SERD standard of care. Among the prespecified subgroup of patients with ESR1 mutations – comprising 36.7% of the trial population – camizestrant showed a 67% reduction in the risk of disease progression or death at a 75mg dose and a 45% reduction at a 150mg dose compared to Faslodex. Efficacy was also seen in patients without a detectable ESR1 mutation, with a 22% and 24% reduction in the risk of disease progression or death respectively for the 75mg and 150mg dose levels. A clinically meaningful PFS benefit was also observed across other prespecified subgroups, including in patients with previously treated with prior cyclin-dependent kinase 4/6 inhibitors, those with lung and/or liver metastases and those with ER-driven disease.